FGFR2 and cholangiocarcinoma: The U.S. Food and Drug Administration (FDA) granted regulatory approvals for the use of the FGFR inhibitor erdafitinib in urothelial carcinoma with FGFR2 or FGFR3 fusions, or FGFR3 mutations and the use of the FGFR inhibitors pemigatinib, infigratinib and most recently futibatinib in CCA with FGFR fusions or rearrangements2–5.